Publications by authors named "Joseph Mrus"

Claim this Profile
L
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Giuliano Rizzardini, Edgar T Overton, Chloe Orkin, Susan Swindells, Keikawus Arasteh, Joseph M Mrus

J Acquir Immune Defic Syndr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Experience with Dolutegravir-Based Two-Drug Regimens.
Douglas Ward, Moti Ramgopal, David J Riedel, Cindy Garris, Shelly Dhir, Joseph Mrus

AIDS Res Treat· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Joseph Mrus

HIV Res Clin Pract· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.
Anthony M Mills, Laurence Brunet, Jennifer S Fusco, Michael B Wohlfeiler, Cindy P Garris, Joseph M Mrus

Infect Dis Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, Giuliano Rizzardini, Axel Baumgarten, Joseph Mrus

N Engl J Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of a Single-Dose Mebendazole 500 mg Chewable, Rapidly-Disintegrating Tablet for and Infection Treatment in Pediatric Patients: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study.
Steven A Silber, Ermias Diro, Netsanet Workneh, Zeleke Mekonnen, Bruno Levecke, Joseph Mrus

Am J Trop Med Hyg· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Joseph Mrus

Lancet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
Stefan Zeuzem, Ralph DeMasi, Alessandra Baldini, Bruce Coate, Donghan Luo, Joseph Mrus

J Hepatol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.
Christos Tsoukas, Louise Gilbert, Trevor Lewis, George Hatzakis, Ron Falcon, Joseph Mrus

ISRN AIDS· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey.
Kathleen Squires, Judith Feinberg, Dawn Averitt Bridge, Judith Currier, Robert Ryan, Joseph Mrus

AIDS Patient Care STDS· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network.
Kelly Gebo, Cindy Voss, Joseph Mrus, Hiv Research Network

AIDS Res Treat· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.
Kimberly Y Smith, Fernando Garcia, Princy Kumar, Judith S Currier, Robert Ryan, Joseph Mrus

J Natl Med Assoc· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use.
Marco daCosta DiBonaventura, Shaloo Gupta, Michelle Cho, Joseph Mrus

AIDS Care· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, Joseph Mrus

AIDS Res Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.
Sally Hodder, Dushyantha Jayaweera, Joseph Mrus, Robert Ryan, James Witek

AIDS Res Hum Retroviruses· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in the gender, race, and clinical experience trial.
Judith Feinberg, Michael Saag, Kathleen Squires, Judith Currier, Robert Ryan, Joseph Mrus

AIDS Res Treat· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.
Andrew M Hill, Michelle Cho, Joseph M Mrus

AIDS Rev· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study.
Ron Falcon, Dawn Averitt Bridge, Judith Currier, Kathleen Squires, Debbie Hagins, Joseph Mrus

J Womens Health (Larchmt)· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.
Judith S Currier, Claudia Martorell, Olayemi Osiyemi, Michael T Yin, Robert Ryan, Joseph Mrus

AIDS Patient Care STDS· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Kristine Patterson, Steven Jennings, Ron Falcon, Joseph Mrus, Angela Kashuba

Antimicrob Agents Chemother· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomics of darunavir.
Dwight S Fullerton, Erik Smets, Guy De La Rosa, Joseph M Mrus

Expert Rev Pharmacoecon Outcomes Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.
James H Willig, Inmaculada Aban, Christa R Nevin, Jiatao Ye, James L Raper, Joseph M Mrus

AIDS Res Hum Retroviruses· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.
Anita J Brogan, Joseph Mrus, Andrew Hill, Anthony W Sawyer, Erik Smets

HIV Clin Trials· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomics of etravirine.
D S Fullerton, Mary Jane Watson, David Anderson, James Witek, Silas C Martin, Joseph M Mrus

Expert Rev Pharmacoecon Outcomes Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.
Judith Currier, Dawn Averitt Bridge, Debbie Hagins, Carmen D Zorrilla, Judith Feinberg, Joseph Mrus

Ann Intern Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis